Shares of Park Ha Biological Technology slid 7.3% to $2.24 on September 11, a day after law firms reiterated allegations of securities fraud and reminded investors of a fast-approaching September 28 deadline to seek lead-plaintiff status in a class-action suit. The stock has now shed roughly 15% in just over a week, and the legal overhang raises pointed questions about whether this China-based company can stabilize before more damage is done. BYAH Drops Again as Fraud Allegations Mount — Is There Any Floor Under a Stock Built on Alleged Smoke and Mirrors?
Shares of Park Ha Biological Technology fell another 7.3% to $2.24 after yet another law firm reiterated securities fraud allegations and the looming September 28 lead-plaintiff deadline, extending a slide that has erased 15% of the stock's value in eight trading days. For a company whose stock once touched $41.49 intraday before losing roughly 93% in a single session, the question isn't just whether the lawsuit succeeds — it's whether BYAH has any credible foundation left.
• A $4 IPO That Briefly Became a Billion-Dollar Phantom
Park Ha's IPO raised just $4.8 million at $4.00 per share.
Yet its market value allegedly surged past $1 billion before collapsing 93% in a single day on July 8, 2025, wiping out more than $1 billion in market capitalization.
Plaintiffs assert that no material corporate development was announced to explain either the stock's rise from the IPO price or its subsequent collapse. That gap — between a tiny capital raise and a billion-dollar valuation — is the heart of the fraud allegations.
• The Lawsuit Alleges a Playbook of Fake Promoters and a Rigged Float
According to the complaint, Park Ha was the subject of a fraudulent stock promotion scheme involving social media misinformation and impersonated financial professionals, its disclosures omitted any reference to artificial trading activity, and its IPO was "intentionally structured with an extremely low public float to enable the manipulation scheme."
The complaint notes the company operated just 39 franchise locations while briefly commanding a valuation exceeding $1 billion — a disconnect that stretches credulity.
• A Drumbeat of Law Firm Notices Is Keeping Selling Pressure Alive Multiple firms — including Rosen Law Firm, Levi & Korsinsky, Bronstein Gewirtz, and SueWallSt — have issued repeated reminders since August, each one refreshing the fraud narrative in headlines and news feeds. The latest Rosen notice was published just hours ago. Every new alert effectively functions as negative advertising, discouraging potential buyers and giving existing holders fresh reasons to sell ahead of the September 28 deadline.
• What Comes Next Could Be Worse Than the Lawsuit Itself Even if the class action takes years to resolve, the near-term damage is structural. A stock trading at $2.24 with active fraud allegations, negligible institutional sponsorship, and a micro-cap float faces a credibility deficit that no press release can fix. The complaint specifically challenges what the IPO prospectus disclosed about "a public float of under 5%," meaning any future capital raise or partnership negotiation starts under a cloud of suspicion. For current holders, the calculus is brutally simple: the legal risk is real, the reputational damage is compounding, and the fundamental business remains far too small to absorb either.